Tislelizumab Receives EU Approval in 3 Indications for First- and Second-Line NSCLC
Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.
Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.
Cancer Questions is a podcast by Dana-Farber Cancer Institute that addresses some of the most common questions surrounding cancer risk and prevention.
This cross-sectional study examines disparities in cancer treatment delay or discontinuation among US patients with cancer and SARS-CoV-2 by race and ethnicity across 5 waves…
Abstract. Clonal hematopoiesis (CH) is a phenomenon of clonal expansion of hematopoietic stem cells driven by somatic mutations affecting certain genes. Recently, CH has been…
Decades of research has dramatically changed cancer care, with more breakthrough treatments on the way thanks to clinical trials that pair patients with oncology experts.
Sattva S. Neelapu, MD, discusses the optimal processes of CAR T-cell therapy administration and the remaining unmet needs in the space.
AbstractBackground:. Ultrafine particles (UFP) are unregulated air pollutants abundant in aviation exhaust. Emerging evidence suggests that UFPs may impact lung health due to their high…
Thoracic anesthesia is a specialized procedure that allows one lung to continue breathing under anesthesia while the other lung is operated on. Stephanie Bradley, M.D.,…
As immunotherapy makes its way into the perioperative setting, a growing number of clinical trials are expanding the evidence base for resectable non-small cell lung…
Abstract. First-generation KRAS G12C inhibitors, such as sotorasib and adagrasib, are limited by the depth and duration of clinical responses. One potential explanation for their…